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Abstract: 
 Vitamin D is generally known to protect against colon cancer; however, its beneficial 
effects are limited to early stages in tumorigenesis. Vitamin D binds to the Vitamin D receptor 
(VDR), which has been shown to meditate colon cancer risk. From previous interventional 
studies, it has been suggested that VDR is down-regulated in tumorigenic cells leading to the 
formation of cancer. Potential mechanisms by which VDR is regulated in tumors were studied. 
Histone deacetylase (HDAC) and Retinoid X receptors (RXR) were studied as potential factors 
that regulate VDR expression. APC
+/∆14 
mice treated with Panobinostat, a HDAC inhibitor, and 
Bexarotene, a RXR agonist, were measured for VDR gene expression along with other VDR 
target genes. The tumor and normal colon tissue were extracted, followed by a gene expression 
analysis using a Real-time qPCR. Mice treated with Panobinostat showed a significant increase 
in the expression of VDR in tumors as compared to normal tissues. This suggests that VDR 
expression may be regulated with HDACs. Mice treated with Bexarotene did not show a 
significant increase in VDR expression; RXR might not be limited by the level of the ligand. Even 
though vitamin D benefits are limited to the early stages in tumor growth, it may be possible to 
develop therapies that enhance vitamin D effects. The drug Panobinostat has been shown to 
up-regulate VDR expression in later stages of tumorigenesis in a mouse model. 
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Introduction/Results: 
Colon cancer is among the three most commonly diagnosed cancers in the world. Each 
year about 100,000 new cases are diagnosed and 50,000 deaths occur on average (Coble, 
2013). There are many factors that contribute to the risk of developing colon cancer including 
diet, genetic predisposition and cellular stress. Nearly two-third of colon cancers are related to 
diet and lifestyle alone (Ingraham et al, 2008). The diagnosis of colon cancer is determined by 
the metastasis of dysplastic colon epithelium to other regions in the body. Traditionally, the 
main types of treatment for colon cancers have been surgery, and chemotherapy (Christakos et 
al, 2013). Depending on the stage of the cancer, these treatments may be combined. While the 
treatment for colon cancers has been the focus of many studies over the past few decades, 
recently studies on early detection and prevention have taken precedence. Techniques such as 
polyp detection and removal through colonoscopies have offered significant protection against 
the development of tumors; however, colon cancer related deaths are still increasing every 
year. Advantages of using chemopreventive mediators such as dietary agents and supplements 
have shown an inverse correlation with the risk of colon cancer. Moreover, these 
chemopreventive agents have been observed to suppress growth pathways, thereby, inhibiting 
cancer formation. These chemopreventive agents that are clinically recognized and still studied 
include folate, vitamin D and calcium to name a few (McCullough et al, 2013). The endpoint of 
this study is polyp recurrence and adenoma formation.  
Recent studies show that cholecalciferol (a form of vitamin D) may be a 
chemopreventive agent that offers protection and even prevention against colon cancers. 
Vitamin D, is a group of fat-soluble prohormones responsible for enhancing intestinal 
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absorption of calcium and phosphate, and regulating mineral homeostasis. In humans, the 
prohormones cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) are obtained from diet, 
fortified foods and supplements; however, only cholecalciferol can be synthesized from 7-
dehydrocholesterol, a type of cholesterol in skin, when exposed to ultraviolet-A light. These two 
vitamin D prohormones are further enhanced in the liver to their active form 1, 25-
dihydrooxycholecalciferol, also known as calciferol. Calciferol mediates all intercellular actions, 
including calcium homeostasis, regulation of cell growth and differentiation, cell adhesion, and 
apoptosis (Ingraham et al, 2008). Ultimately, vitamin D offers cancer preventative benefits 
through the transcription of target genes such as p21 and Cdh1, cell cycle regulator and tumor 
suppressor, respectively. Studies by Cuomo RE, Mohr SB, Gorham ED, et al. (2013) showed that 
higher exposure to sunlight and/or a diet high in vitamin D correlated inversely with colon 
cancer development. To study the protective effect of vitamin D supplementation, we used a 
mouse genetic model of colon cancer to analyze its response to different levels of dietary 
vitamin D. 
Initial studies using APC
+/∆14 
mice tested a trend in vitamin D protection. Higher 
concentrations (2500 IU compared to 250 IU) of vitamin D appear to suggest a lower tumor 
count (figure 1). 
 In order for vitamin D to induce a response, it must bind to the vitamin D
(VDR), a class of the nuclear receptor superfamily (Christakos et al, 2013). VDRs are found in 
many cell types including heart, muscle, breast, colon, prostate, brain, kidney, bone, intestine, 
osteoblasts, and immune cells.  Studies have shown th
interactions in normal and tumor colon tissues.
Vitamin D and VDR interact. 
Recently, it has been observed that VDR expression is frequently suppressed in 
Early in tumorigenesis Vitamin D is effective; however,
means that vitamin D is not actively binding to VDR and therefore offering its protective 
mechanisms (Rosa et al, 2013). For example, Hartman et al. 
  
e importance of vitamin D
 Figure 2 shows a simplified visual of how 
 
 this is less clear in adenomas
(2005) conducted a clinical study 
Figure 1: Comparison of colon tumor 
count in APC
+/∆14
 mice cells of high
(2500IU) and low (250IU) 
concentrations. Higher Vitamin D 
concentration show trends in lower 
colon tumor count.  
(Provided by Dr. Masako Nakanishi 
and Dr. Daniel Rosenberg at the 
UCHC). 
Figure 2: Simplified visual of 
vitamin D and VDR interaction.
When the vitamin D binds to the 
VDR, it is transcribed to produce 
genes that lead to regulation of 
cellular growth.
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 called the Polyp Prevention Trial, which found that higher vitamin D i
in reducing the risk of adenomas. This ultimately means that there is a disruption in the vitamin 
D-VDR interaction. Furthermore,
VDR expression in tumor tissues. As a result, the concentration of vitamin D that 
utilized within the tumor cells is limited. 
Nakanishi Masako, it was shown in a cross
(figure 3). 
Our lab used APC
+/∆14 
mice to confirm the initial observations of VDR down
tumors. We found that VDR is down
and Cdh1, were also down-regulated, adding to the evidence for VDR suppression in tumors 
(figure 4). By understanding how VDR expression is regulated in tumor cells, we may be ab
gain insight into the mechanism of tumor cell progression. 
ntake was not significant 
 Knackstedt, Moseley, Sun & Wargovich (2013) 
Figure 3 shows an immunostaining provided by Dr. 
-section of mice tissue that VDR is abse
  
-regulated by fivefold. Moreover, VDR target genes, p21 
 
Figure 3: Immunostaining of VDR in 
APC
+/∆14
 mice colon tumor cells.
Brown staining represents the 
presence of VDR. Blue staining is 
used as a counter stain for cells that 
lack VDR. The areas of blue also 
differentiated cells 
cells. Additionally the blue areas
show aberrant cellular proliferation 
and dysplastic neoplasia. 
(Provided by Dr. Nakanishi Masako)
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 HCT and HT29 colon cancer cells were used to model human colon cancer. From the cell 
studies it was suggested that histone deacetylase (HDAC) may be a possible regulator of VDR. 
HDACs ultimately decrease gene transcription by binding to the histones and removing acetyl 
groups, thereby allowing DNA to tightly bind to the histone. A simplified model for the actions 
of HDACs is shown in figure 5. HDAC expression was also measured in the 
gene expression analysis in the APC
significantly higher expression of HDACs than normal cells (figure 6). 
 
APC
+/
+/∆14
 mice model, we found that tumor cells have a 
 
 
Figure 4: Comparison of VDR, p21, 
and Cdh1 expression in normal and 
tumor colon cancer tissues
APC
+/∆14
 mice. As compared to
colon, tumor colon tissue
significantly lower expression of VDR, 
p21 and Cdh1 genes. 
Figure 5: Simplified visual of 
HDAC and VDR
HDAC will inhibit 
transcription of VDR, thereby 
decreasing VDRs in the cell. 
7 
∆14
 mice. Using a 
 from 
 normal 
 have 
 interaction. 
the 
 
 VDR is known to interact with the retinoid x receptor (RXR), 
heterodimerizes with other nuclear receptors.
interaction. It was suggested that RXR
thereby limiting the VDR expression. Moreover, studies by 
that VDR and RXR are down-regulated in a mouse model. 
expression levels in the APC
+/∆14
 
in both normal and tumor tissues. It was found that RXRa, RXRb and RXRg were significantly 
down-regulated in tumors as compared to normal tissues (figure 8).
 
a nuclear receptor that 
 Figure 7 shows a simplified view of this 
-VDR interaction may be interrupted in tumor cells, 
Knackstedt et al. (2013) 
We therefore determined the RXR 
model. Initially, a gene expression analysis for RXRs was done 
 
 
Figure 6: Comparison of HDACs 
expression in normal and tumor colon 
cancer tissues from APC
compared to the normal cells, tumor 
cells have higher expression of HDACs 
on average. 
Figure 7: Simplified visual of 
RXR and VDR
RXR will heterodimerize with 
VDR, thereby allowing VDR 
to bind to the response 
element on the RNA and be 
transcribed.  
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 A HDAC inhibitor, Panobinostat, was used to measure the correlation between HDACs 
and VDR expression. Panobinostat was chosen because it is frequently used in preclinical 
studies on HDACs. An RXR agonist, Bexarotene, was used to measure the relationship be
RXR and VDR expression. This was also chosen because it is widely used in preclinical studies.  
Initially it was proposed that HDACs may be a possible mechanism by which VDR is 
down regulated. Figure 9 shows how this was tested. Panobinostat, the HD
inhibit the HDAC, which would not inhibit VDR. Thereby, allowing VDR to be transcribed. 
Vitamin D to would bind to the VDR and allow for anti
interventional study and gene expression analysis on the 
the mice treated with Panobinostat showed a significantly higher VDR expression as compared 
to the mice that weren’t treated with Panobinostat 
validity of the observed VDR expre
the VDR, was measured. It was found that the relative expression of p21 was also significantly 
higher in mice treated with Panobinostat. 
The results of the Panobinostat treated mice suggest that the HDAC up regulation in 
mice tumors are correlated with the VDR down regulation. This may occur because HDACs are 
 
AC inhibitor, would 
-tumorigenic effects. By doing an 
APC
+/∆14
 mice, it was discovered that 
(figure 9). Moreover, in order to assure the 
ssion, the relative expression of p21, a downstream target of 
 
Figure 8: Comparison of RXR 
expression in normal and tumor 
colon cancer tissues from APC
mice. As compared to the normal 
tissues, tumor tissues
expression of RXRs 
9 
tween 
 
+/∆14
 
 have lower 
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binding to the DNA and decreasing the transcription of the DNA; ultimately, VDR gene is not 
being transcribed and the VDR proteins are not made. The lack of VDRs will limit the vitamin D 
utilization within the organism and lead to lower protection against tumor formation.  
As for the RXR experiment, it was initially proposed that Bexarotene would allow RXR to 
bind to the VDR, which would subsequently bind to the DNA and transcribe specific anti-
tumorigenic genes (figure 10). The results from the Bexarotene treated mice showed a slight 
increase in the VDR expression, which was not significant (figure 10). This means that the RXR 
action may not be limited by the level of the ligand but does not mean that the RXR are not 
factors for the down-regulation of VDR. The RXRs may play an important role in VDR regulation 
but it may not be direct.  
  
  
Figure 9: Pathway by which HDACi, Panobinostat, acts to suppress unregulated cell growth. 
Relative expression of VDR and p21 in cells of APC
Normally, the vitamin D will bind to the VDR and regulate cell growth. 
cells, the VDR expression is low. As a result, vitamin D’s health benefits will be limited and 
uncontrolled cellular growth may occur leading to colon cancer. Panobinostat, a HDAC 
inhibitor (HDACi), prevents HDACs from functioning. Thereb
and subsequently limiting uncontrolled cellular growth. Furthermore, an increase in p21 
expression with the Panobinostat confirms the reduction in uncontrolled cellular growth.
 
+/∆14
 mice treated with Panobinostat. 
However, in tumor 
y, allowing VDR gene expression 
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Methods 
Figure 10: Pathway by which Bexarotene a
Relative expression of VDR in normal and tumor cells of APC
Bexarotene. Bexarotene, a RXR agonist, will stimulate RXR binding to VDR which will 
transcribe the VDR gene ultimately leading to th
The graphs show that the addition of Bexarotene does not result in significantly higher VDR 
expression in colon tumor cells.
 
cts to suppress unregulated cell growth. 
+/∆14
 mice treated with 
e decrease in unregulated tissue growth. 
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Treatment of tumor-bearing/normal mice and tissue extraction 
APC
+/∆14 
mice were used to model the vitamin D-VDR expression seen in colon cancer. 
APC
+/∆14 
mice have a heterozygous knockout for the APC gene, which gives them a tumor 
predisposition phenotype.  
APC
+/∆14 
mice were treated at the University of Connecticut Health Center (Farmington, 
CT). They were allowed access to laboratory rodent chow (Laboratory Rodent Diet 5001; PMI 
Nutrition International, Richmond IN) and water. Ten mice were fed a high vitamin D (2500 IU) 
diet. At five weeks of age, five of those mice were treated with Panobinostat (LBH-589) for nine 
weeks. The other five mice were raised normally. Concurrently, another eight mice were raised 
on a low vitamin D (250 IU) diet. Of those, three were injected with Panobinostat while the 
other five were raised normally. After the final dose, all the mice were euthanized. The tumor 
and adjacent normal tissues from the colons and liver were separately collected for analysis.  
Another set of 18 mice were treated as above but were injected with Bexarotene 
instead of Panobinostat. The same collection procedure as cells treated with Panobinostat was 
used here as well. RNA was prepared from the samples by grinding and storing in TRIzol 
reagent.  
RNA extraction 
 Tissues were suspended in 200uL of TRIzol reagent (Life Technologies, Carlsbad, CA) in 
microfuge tubes. Next, at least ten minutes were allowed in order for the TRIzol to homogenize 
the samples based on molecular size. Afterwards, 200uL of chloroform was added to the 
microfuge tubes and shaken vigorously for 15 seconds, lysing the cells and allowing the RNA to 
be released. The samples were centrifuged at 12,000rpm for fifteen minutes at 4
o
C. After the 
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centrifugation was complete, the upper aqueous layer of the samples was removed and 
pipetted into new tubes. To the new tubes 500ul of isopropanol was added and incubated for 
ten minutes before they were centrifuged at 12,000rpm for ten minutes at 4
o
C. The 
centrifugation left an RNA pellet at the bottom of the tube, which was isolated by removing the 
supernatant from the tube. The RNA pellet was washed with 75% ethanol and centrifuged again 
at 12,000rpm for five minutes at 4
o
C. Finally, after centrifugation, the supernatant was 
removed, completely leaving behind the RNA pellet, which was resuspended in RNase-free 
water and store at 70
o
C.   
RNA quantification 
 In order to quantify the RNA concentration in the samples, Thermo Scientific NanoDrop 
8000 Spectrophotometer (cat. #13-400-413) from Fisher Scientific (Waltham, MA) was used. 
Initially, the NanoDrop 8000 was blanked by using RNA-free water. Then a single drop of the 
mice tissue RNA was pipetted into the NanoDrop apparatus and the concentration was 
measured. This step allowed for the confirmation that the samples actually contained RNA 
before proceeding to reverse transcribe them to cDNA.  
Reverse transcription 
 Using the quantified concentrations of RNA, it was necessary to calculate the amount of 
the samples needed to make 10ul solutions in H2O. The mixtures were added to new microfuge 
tubes with 10ul master mix (H2O, 10x reverse transcription buffer, 25x dNTP mix, 10x random 
primers, and reverse transcriptase ) (Life Technologies, Carlsbad, CA).. The tubes were 
centrifuged at room temperature, then placed into the My Cycler: Bio-RAD (Conquer Scientific 
San Diego, CA). My Cycler is a thermal cycler that transcribes the RNA into cDNA. 
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Real-Time qPCR 
 In order to measure the expression of the specific probes on the samples, a Fast Real-
Time qPCR was used. The ACTB was our control gene to which all the other probe expressions 
were compared. VDR is the gene for the vitamin D receptor, SAHA is a HDAC inhibitor, SNAIL1/2 
are transcription repressors, and 5’-AZA is a DNMT inhibitor. Using the TaqMan gene expression 
assay (Life Technologies, Carlsbad, CA), it was possible to do a real-time qPCR to measure gene 
expression. In order to run a real-time qPCR, the probes were thawed at room temperature. 
Using the calculated concentrations, the master mix was prepared by mixing the TaqMan gene 
expression Master Mix and RNase-free water in a microfuge tube. Calculated amounts of cDNA 
were pipetted into new microfuge tubes. To these tubes, calculated amounts of the master mix 
were added. Using a 96-well microtiter reaction plate, 8ul of the cDNA/master mix were added 
to the appropriate wells. A repeater pipette was used to add 2ul of the specific probes of 
interest to each of the wells. The plate was sealed thoroughly and loaded into an Applied 
Biosystems 7500 Fast Real-time PCR System.  
Data Analysis 
 The comparative CT method was used to analyze the data andquantify  gene expression. 
Student’s t-test was used for statistical group analysis. P-values below 0.05 were considered as 
statistically significant.  
 
 
Discussion/Literature Review 
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Initially, there were a few possible epigenetic mechanisms that were considered for 
exploration. They included SNAIL/SLUG proteins, HDACs, RXRs, and DNA methyltransferase 
(DMNT). However, due to time constraints and evidence from literature, only two of the 
mechanisms were thoroughly studied. The following review of literature will present past 
research studies that analyzed various means of VDR down regulation in tumor cells. Rationales 
for studying HDACs and RXR will be discussed. 
SNAIL/SLUG protein effects on VDR regulation  
 Larriba, Bonilla & Munoz (2010) investigated a less known mechanism of VDR down-
regulation, the up-regulation of transcription factors SNAIL1/SLUG. These transcription factors 
bind to E-box sequence and recruit HDACs, which repress the expression of the gene. 
Moreover, the overexpression of SNAIL1 and SLUG induces the epithelial-to-mesenchymal 
transition (EMT), meaning that the tissue loses its epithelial characteristics and acquires 
mesenchymal fibroblastic phenotype. As a result, the cells develop migratory properties 
favoring tumor invasion and metastasis. Using phase-contrast imaging and confocal laser 
immunofluorescence imaging they suggested that the tumor cells that did not express 
SNAIL1/SLUG were normal epithelial cells, and those that did express SNAIL1/2 had 
mesenchymal cell characteristics.  
 Normal and tumor biopsies from approximately one hundred colon cancer patients 
were used to test for SNAIL1, SLUG and VDR RNA expression. SNAIL1 and SNAIL2 were present 
in low or no quantities in normal colonic tissue, but were expressed 60-70% in colon tumor 
tissue. In addition, tumors that express SNAIL1 and SNAIL2 showed a strong VDR down-
regulation.  
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  Palmer et al., (2004) also looked at the significance of SNAIL proteins on human colon 
cancer cells. Their study examined the relationship between SNAIL and calcitriol, a form of 
vitamin D, suppression. 
One of the beneficial effects of calcitriol is the expression of E-cadherin, a protein 
important in cellular adhesion within a tissue. It gives the cell membrane strength and support. 
If E-cadherin expression is suppressed then the cell loses some of its cellular adhesion and 
becomes prone to migration. Palmer et al. (2004) found that the expression of E-cadherin was 
reduced by SNAIL. Using chromatin-immunoprecipitation (ChIP) assays, they also showed that 
SNAIL is recruited on the native VDR promoter in vivo. This further adds to our understanding of 
SNAIL-induced suppression of VDR.  
Our studies on the SNAIL/SLUG gene expression showed that they were up-regulated in 
tumors as compared to normal tissue by three folds (Figure 11).  However, the SNAIL/SLUG 
expression was expressed mostly in tumor stroma and not the cells themselves (figure 12). As a 
result, SNAIL/SLUG was not studied in our study. It is important to note that SNAIL/SLUG recruit 
HDACs in order to suppress gene expression. As previously mentioned, HDACs are shown to be 
highly expressed in tumors; thus, they were studied. 
  
HDAC effects on VDR regulation
A study done by Seuter, Heikkinen, & Carlberg
(HDAC) and its effects on VDR suppression
groups from a lysine amino acid 
tightly thusreducing the expression of certain genes. Seuter et al. proposed a mechanism in 
which HDACs are up-regulated in a cell, which le
added validity to the claim that HDACs may be a regulator of VDR expression in colon cancer 
cells. 
 
 
 
 
 (2012) looked at the Histone Deacetylase 
. HDACs are a class of enzymes that remove
on a histone, allowing the histones to wrap the DNA more 
d to VDR down-regulation. This study further 
Figure 11 shows SNAIL/SLUG up 
regulated in tumors. 
regulation of SNAIL/SLUG was 
observed mostly in the tumor 
stroma and not the tumor itself.
Figure 12 shows an 
immunostaining of SNAIL/SLUG 
expression in colon tumor tissue. 
Areas of brown staining represent 
the presence of SNAIL/SLUG. Areas 
of blue are counterstaining for the 
absence of SNAIL/SLUG. The 
SNAIL/SLUG proteins are located in 
the tumor stroma, not the tumors 
themselves. 
(Provided by Dr. Nakanishi Masako)
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RXR effects on VDR regulation 
Knackstedt, Moseley, Sun & Warqovich (2013) studied suppression of Retinoid X 
receptor a (RXRa), heterodimerization with VDR and its relation to the SNAIL protein in human 
ulcerative colitis and colitis-associated cancer (CAC). Normally, when VDR binds to the 
promoter sequence it is heterodimerized with an RXRa, which allows for the VDR to bind to the 
correct sequence on the VDR gene. It was suggested in tumor cells that the VDR and the RXRa 
may be compromised. This means that the expression of both VDR and the RXRa is suppressed.  
In order to explore the mechanism behind this study, Knackstedt et al. (2013) proposed 
a link between the VDR-RXRa suppression and the SNAIL protein’s up-regulation. Using a real-
time PCR analysis they were able to show a significant up-regulation of TNFa, an upstream 
regulator of SNAIL, and SNAIL RNA. Moreover, with immunohistochemistry techniques they 
were able to show that the SNAIL proteins were evident in ulcerated areas in the colorectal 
cancer (CRC) models, thus, in the same locations where RXRa and VDR were down-regulated. 
The study by Knackstedt et al. (2013) suggests that SNAIL may be a factor for RXR down-
regulation. However, our results (figure 9) show that SNAIL is actually down-regulated in 
tumors. This may mean that SNAIL is not a direct reason for RXR down regulation. However, 
RXR down regulation in tumors was noted for further exploration.  
DMNT effects on VDR regulation 
Marik, Fackler, Gabrielson et al. (2010) tested to see if hypermethylation of the CpG 
regions, multiple repeated sequences of cytosine and guanine nucleotides linked by 
phosphodiester bonds, near the promoter of the VDR gene would silence the expression of 
VDR. First, calcitriol binds to the VDR that goes into the nucleus and binds to the Vitamin-D 
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response element (VDRE), a sequence on the VDR gene. In normal cells, the transcription of the 
VDR gene is uninhibited and promotes the transcription of VDR mRNA which ultimately leads to 
the production of VDR protein that allows for more calcitriol to bind.  
 Marik et al. (2010) aimed at studying VDR expression in breast cancer cells. Using 
immunohistochemistry they found that the expression of VDR was higher in differentiated cells 
than in proliferating cells. While many previous studies focused on the alteration of histone 
acetylation in the VDR promoter, Marik et al. (2010) pointed towards altered DNA methylation 
patterns as a proposed mechanism for VDR suppression in tumor cells. They investigated to see 
if methylation-induced silencing of VDR in breast cancer might account for the calcitriol 
insensitivity. Methylation of a nucleotide inhibits the transcription of that nucleotide; as a 
result, whatever a certain nucleotide sequence transcribes will be suppressed if there is 
methylation on it. In the case of VDR, methylation will result in decreased expression of VDR 
mRNA.   
By means of in-silico techniques, they were able to find three CpG islands in an area 
spanning from -790 bp upstream to +380 bp downstream relative to the primary transcription 
start site. They performed a bisulfite sequencing analysis in order to look for methylation in 
these regions with an interest in the region closest to the promoter. They found that the CpG 
regions had relatively higher methylation in tumor cells as compared to normal cells (Marik et 
al. 2010). 
Main findings of this study reported that demethylation restores the effects of calcitriol 
in breast cancer. They treated breast cancer cells and normal breast epithelial cells for 96hours 
with calcitriol, with a demethylating agent AZA (5’ deoxy-azacytidine) and with calcitriol and 
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AZA. They discovered that the effects of calcitriol were amplified when induced with AZA, with 
a greater antiproliferative effect than with either agent alone. This meant that the overall 
expression of VDR increased with calcitriol and AZA combined (Marik et al. 2010). The results of 
this study indicate that methylation of the CpG regions may be the underlying cause for the 
suppression for VDR in tumor cells. However, the result of this study were limited to breast 
cancer cells.  
HCT and HT29 colon cancer cells were used to test the effect of methylation on VDR 
expression. In order to see how methylation will effect VDR gene regulation, we looked at DNA 
methyltransferase (DMNT), a family of enzymes that catalyze the transfer of methyl groups to 
DNA. Using the drug 5-Azacytidine (5-AZA), an enzyme that inhibits DMNTs, VDR expression 
was measured via a gene expression analysis. The results showed no significant increase in VDR 
expression in the HCT cells and a relatively higher increase in the VDR expression in the HT29 
cells (figure 11). It was determined that the results were not promising enough to study DMNTs 
in a mouse model, at least from the initial data.  
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 While the goal early on in this project was to study the effect of HDACs, RXRs, 
SNAIL/SLUG and DMNT on VDR expression, initial studies determined that HDACs and RXRs 
were more effective than SNAIL/SLUG and DMNT. Therefore, in the last part of this experiment, 
HDACs and RXRs were studied more thoroughly.  
 
Future Directions   
 The results from these experiments allow for future studies to focus on finding which 
specific HDACs lead to the significant increase in VDR expression, which will allow for a more 
Figure 11: Measuring VDR and p21 expression using Actin-Beta (control), SAHA and 5AZA in HCT 
and HT29 colon cancer cells.  
HCT  HT29  
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targeted therapy. Additionally, other intracellular proteins that affect VDR expression need to 
be studied. Finally, in the long run, the goal is to develop therapies for preventing the down-
regulation of VDR in colon tumors. By studying the various mechanisms that control and 
regulate VDR, it may be possible to design therapies that will improve colon cancer prevention.  
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